NCT06369077

How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?

Cross-over Comparison of Latanoprost QOD With Dor-tim QAM to Tim-brim-dor-bim(Atoprost) qd or Lat QD With Dor-tim BID

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: CT Glaucoma Associates · Academic / Other
• Sex: All
• Age: 25 Years – 90 Years
• Healthy volunteers: Accepted

Summary

IOP effect of half-dose latanoprost dorzolamide-timolol will be compared to full dose. Further comparison will be made timolol-brimonidine-dorzolamide-bimatoprost. Dry eye effects of the different treatments will be assessed.

Detailed description

Subjects will have baseline IOP measurements (7-9 am and 3-5 pm) after using using latanoprost every other day and dorzolamide-timolol every morning. They will then randomly be assigned in phase 2 to either: double the frequency to latanoprost daily and dorzolamide-timolol twice daily; or use every morning compounded timolol-brimonidine-dorzolamide-bimatoprost. IOP measurements will be repeated 3 weeks after using the phase 2 medications. For phase 3, subjects will use the treatment to which they were not assigned in phase 2, and IOP measurements will again be repeated 3 weeks later. At each study visit, dry eye signs will be assessed and brief dry eye survey will be administered.

Conditions

• Glaucoma, Open-Angle
• Glaucoma; Drugs

Interventions

Type	Name	Description
DRUG	dorzolamide/timolol	Compare half-frequency dosing of latanoprost and dorzolamide/timolol to full dosing. Compare also to timolol/brimonidine/dorzolamide/bimatoprost

Timeline

• Start date: 2024-04-22
• Primary completion: 2024-07-30
• Completion: 2024-07-30
• First posted: 2024-04-16
• Last updated: 2024-08-23

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study